中國抗體-B(03681.HK)擬折讓約16.12%發行1.82億股 淨籌3.69億港元
格隆匯7月22日丨中國抗體-B(03681.HK)公告,於2025年7月22日,公司與二十三名認購人訂立二十三(23)份認購協議,據此,公司有條件同意發行而認購人有條件同意認購合共182,072,400股新股份,認購價爲每股認購股份港幣2.03元。
於本公告日期,公司已發行股份爲1,204,565,936股。認購股份合共相當於公司於本公告日期的已發行股本約15.12%;認購價乃由公司與各認購人在參考股份近期的交易表現、集團的業務前景及財務狀況以及當前市況後經公平磋商而達致。每股認購股份認購價定爲港幣2.03元,較股份於2025年7月22日(即認購協議日期)在聯交所所報每股收市價港幣2.42元折讓約16.12%;所得款項淨額合共將約爲港幣3.69億元,即每股認購股份淨認購價約爲港幣2.03元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.